Some 5 million Americans have Alzheimer's disease, with more cases sure to develop as the baby boomer generation ages. New potential discoveries are on the horizon. But, as Dr. William Thies, chief medical and scientific officer for the national office of the Alzheimer's Association, tells host Bruce Japsen, significant challenges and obstacles also lie ahead for these potential ground-breaking discoveries.
New Frontiers and Challenges for Alzheimer's Drugs
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Some 5 million Americans have Alzheimer's disease, with more cases sure to develop as the baby boomer generation ages. New potential discoveries are on the horizon. But, as Dr. William Thies, chief medical and scientific officer for the national office of the Alzheimer's Association, tells host Bruce Japsen, significant challenges and obstacles also lie ahead for these potential ground-breaking discoveries.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
Clinician's Roundtable
Challenges in AI-Driven Dermatology: Understanding Current Limitations
<p>Challenges in AI-Driven Dermatology: Understanding Current Limitations</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
ACC Action Center
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
<p>Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?